DNAprint Genomics (DNAG)

[ann441j]

Wonder why this is still on DNAP website?

Subsidiaries and affiliates
http://www.biofrontera.com

Biofrontera AG is establishing a specialty pharmaceutical business for research and development in dermatology and inflammation. The company’s state-of-the-art laboratory facilities in Leverkusen, Germany, are modern and fully-equipped with sufficient space for projected growth and market expansion.

Biofrontera’s specific expertise lies in the characterization of the pharmacological properties of drug candidates in vitro and in vivo. Biofrontera’s goal is to build a specialty pharmaceutical company with wholly owned products, initially for dermatologic applications. In the future, other pharmaceuticals for larger markets will result from Biofrontera’s in-house research.

In addition, Biofrontera AG holds a wholly-owned subsidiary, Biofrontera Pharmaceuticals GmbH. Biofrontera Pharmaceuticals GmbH has three drugs in pre-clinical and clinical development. Two drugs are in phase II trials; the leading compound is expected to enter the market in 2007/08. Click here to get the latest Biofrontera Bond update.

Ann